

# GOES WHERE MIGRAINE PILLS DON'T

DOES WHAT MIGRAINE PILLS CAN'T<sup>1-4</sup>

Please show this to your healthcare provider to learn more about Trudhesa®

Trudhesa Direct™: Prescribing is easy through ASPN and Phil pharmacies

Hassle-free prescribing for you, at-home delivery and \$0 copay for eligible patients.\*



Trudhesa is the first migraine treatment that uses advanced Precision Olfactory Delivery (POD®) technology to consistently deliver dihydroergotamine mesylate (DHE) to the upper nasal space.<sup>5</sup>

- DHE has a 70+ year history of proven effectiveness in the treatment of migraine<sup>6,7</sup>
- The Trudhesa pivotal safety study is the largest longitudinal study ever conducted with DHE using nasal spray delivery<sup>1</sup>
- POD gently and consistently delivers DHE to the highly permeable and vascular-rich upper nasal space<sup>5</sup>
- Upper nasal space delivery enables rapid absorption into the circulation<sup>8,9</sup>

Discover Trudhesa, for rapid, sustained, consistent relief, even when taken late into an attack.<sup>5,9</sup>



For more ordering information and Prescribing Information, visit [trudhesaHCP.com/Prescribe](https://trudhesaHCP.com/Prescribe) or use your smartphone camera to scan the QR code.

**References:** 1. Trudhesa. Prescribing information. Impel Pharmaceuticals; 2021. 2. Silberstein SD, Shrewsbury SB, Hoekman J. Dihydroergotamine (DHE) – then and now: a narrative review. *Headache*. 2020;60(1):40–57. 3. Wells RE, Markowitz SY, Baron EP, et al. Identifying the factors underlying discontinuation of triptans. *Headache*. 2014;54(2):278–289. 4. Sheftell FD, Feleppa M, Tepper SJ, Volcy M, Rapoport AM, Bigal ME. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. *Headache*. 2004;44(7):661–668. 5. Smith TR, Winner P, Aurora SK, Jeleva M, Hocevar-Trnka J, Shrewsbury SB. STOP 301: a phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD®) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients [published online ahead of print, 2021 Aug 7]. *Headache*. 2021;10.1111/head.14184. doi:10.1111/head.14184. 6. US Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>. Accessed August 24, 2021. 7. Saper JR, Silberstein S, Dodick D, Rapoport A. DHE in the pharmacotherapy of migraine: potential for a larger role. *Headache*. 2006;46(suppl 4):S212–S220. 8. Data on File. Impel Pharmaceuticals. INP104–301. Clinical Study Report. 2020. 9. Shrewsbury SB, Jeleva M, Satterly KH, Lickliter J, Hoekman J. STOP 101: a phase 1, randomized, open-label, comparative bioavailability study of INP104, dihydroergotamine mesylate (DHE) administered intranasally by a I23 Precision Olfactory Delivery (POD®) Device, in healthy adult subjects. *Headache*. 2019;59(3):394–409.

## Indication and Important Safety Information

### Indication

Trudhesa is used to treat an active migraine headache with or without aura in adults. Do not use Trudhesa to prevent migraine when you have no symptoms. It is not known if Trudhesa is safe and effective in children.

\*Please see following page for terms and conditions.

Please see Important Safety Information, Prescribing Information, including Boxed Warning, and Medication Guide at [trudhesa.com](https://trudhesa.com).

 **Trudhesa®**  
(dihydroergotamine mesylate) nasal spray  
0.725 mg per spray

#### **\*Terms and Conditions:**

Eligible, commercially insured patients may pay as little as \$0 for **Trudhesa**<sup>®</sup> (dihydroergotamine mesylate). If **Trudhesa** is not covered by the patient's commercial insurance plan, the patient pays as little as \$0 for the first box (4 Pods) and as little as \$0 for each additional box up to four (4) boxes per calendar year. Additional restrictions may apply. See below for full eligibility criteria, terms and conditions.

**Restrictions:** This offer is valid in the United States only. Offer is available if a patient has a prescription, is commercially insured and is 18 years or older. Offer is not valid for patients who use any state or federal government-funded healthcare program to cover a portion of medication costs, such as Medicare (including Medicare Part D), Medicaid, Medigap, TRICARE, Department of Defense (DOD), Veterans Administration (VA), patients who are cash-paying or where prohibited by law. By using this offer, the patient certifies that he or she will comply with any terms of his or her insurance plan. It is illegal to (or offer to) sell, purchase, or trade this offer. Void where prohibited by law. This program does not constitute health insurance. The parties reserve the right to rescind, revoke or amend this offer without notice at any time.

### **Important Safety Information**

Serious or potentially life-threatening reductions in blood flow to the brain or extremities due to interactions between dihydroergotamine (the active ingredient in Trudhesa) and strong CYP3A4 inhibitors (such as protease inhibitors and macrolide antibiotics) have been reported rarely. As a result, these medications should not be taken together.

#### **Do not use Trudhesa if you:**

- Have any disease affecting your heart, arteries, or blood circulation
- Are taking certain anti-HIV medications known as protease inhibitors (such as ritonavir or nelfinavir)
- Are taking a macrolide antibiotic such as clarithromycin or erythromycin
- Are taking certain antifungals such as ketoconazole or itraconazole
- Have taken certain medications such as triptans or ergot-type medications for the treatment or prevention of migraine within the last 24 hours
- Have taken any medications that constrict your blood vessels or raise your blood pressure
- Have severe liver or kidney disease
- Are allergic to ergotamine or dihydroergotamine

#### **Before taking Trudhesa, tell your doctor if:**

- You have high blood pressure, chest pain, shortness of breath, heart disease; or risk factors for heart disease (such as high blood pressure, high cholesterol, obesity, diabetes, smoking, strong family history of heart disease or you are postmenopausal, or male over 40); or problems with blood circulation in your arms, legs, fingers, or toes.
- You have or had any disease of the liver or kidney.

- You are taking any prescription or over-the-counter medications, including vitamins or herbal supplements.
- You are pregnant, planning to become pregnant or are nursing, or have ever stopped medication due to an allergy or bad reaction.
- This headache is different from your usual migraine attacks.

The use of Trudhesa should not exceed dosing guidelines and should not be used on a daily basis.

Serious cardiac (heart) events, including some that have been fatal, have occurred following the use of dihydroergotamine mesylate, particularly with dihydroergotamine for injection, but are extremely rare.

You may experience some nasal congestion or irritation, altered sense of taste, sore throat, nausea, vomiting, dizziness, and fatigue after using Trudhesa.

Contact your doctor immediately if you experience:

- Numbness or tingling in your fingers and toes
- Severe tightness, pain, pressure, heaviness, or discomfort in your chest
- Muscle pain or cramps in your arms or legs
- Cold feeling or color changes in 1 or both legs or feet
- Sudden weakness
- Slurred speech
- Swelling or itching

The risk information provided here is not comprehensive. To learn more, talk about Trudhesa with your healthcare provider or pharmacist. The FDA-approved product labeling can be found at [www.trudhesa.com](http://www.trudhesa.com). You can also call 1-833-TRUDHESA (1-833-878-3437) for additional information.

**Please see Important Safety Information, Prescribing Information, including Boxed Warning, and Medication Guide at [trudhesa.com](http://trudhesa.com).**



IMPEL, POD, TRUDHESA, TRUDHESA DIRECT, and the Impel and Trudhesa Logos are trademarks of Impel Pharmaceuticals LLC. Other trademarks are the property of their respective owner(s).  
© 2025 Impel Pharmaceuticals LLC. All Rights Reserved.  
US-TRU-2100095 07/2025

